8/31/2023 0 Comments Kite pharma yahoo financeKite, which has gained nearly 11 percent in the past five trading days, changed hands recently at $63.19, up $0.47. Separately, Kite on Tuesday unveiled a partnership with bluebird bio Inc (NASDAQ: BLUE) to develop and market T-cell therapies for HPV-associated cancers. The IND application would enable clinical trials to commence. It has also filed regulatory application for the candidate in the EU. Kite also hopes to file an investigational new drug application in the first half of 2016 related to two further anti-cancer antigens, Amin said. Kite Pharma (KITE) shares hit a new 52-week high as the company's CAR-T therapy with axicabtagene ciloleucel nears an FDA nod. "Those are three very large commercial markets," Newman said. That study is aimed at gauging toxicity of the drug, according to Newman, who also expects Kite to start human testing later this year on drugs related to a form of human papillomavirus as well as colorectal, lung, and pancreatic cancers. The company expects to release interim results of a related lymphoma study in December at the annual meeting of the American Society of Hematology. View Ultragenyx Pharmaceutical (location in California, United States, revenue. (KITE) announced results from phase I trial, ZUMA-3, on lead candidateKTE-C19 (axicabtagene ciloleucel) in adults with high burden relapsed/refractory acute lymphoblastic. Kite may file a biologic license application next year for its KTE-C19 drug as a treatment for diffuse large B-cell lymphoma, according to Amin. Canaccord's John Newman also reaffirmed a Buy rating on Kite with a $90 target.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |